Nano Coronavirus Recombinant Vaccine Taking Graphene Oxide as Carrier
Abstract: The invention belongs to the field of nano materials and biomedicine, and relates to a vaccine, in particular to development of 2019-nCoV coronavirus nuclear recombinant nano vaccine. The invention also comprises a preparation method of the vaccine and application of the vaccine in animal experiments. The new corona vaccine contains graphene oxide, carnosine, CpG and new corona virus RBD; binding carnosine, CpG and neocoronavirus RBD on the backbone of graphene oxide; the CpG coding sequence is shown as SEQ ID NO 1; the novel coronavirus RBD refers to a novel coronavirus protein receptor binding region which can generate a high-titer specific antibody aiming at the RBD in a mouse body, and provides a strong support for prevention and treatment of the novel coronavirus.
Preparation and Application of Pachyman Nano Adjuvant Based on Graphene Oxide and Adjuvant/Antigen Co-delivery Vaccine
Abstract: Preparation and application of pachyman nano adjuvant and adjuvant/antigen co-delivery vaccine based on graphene oxide, belonging to the field of medicines. The invention comprises a pachyman nano adjuvant which is formed by taking a nano graphene oxide material as a carrier and pachyman loaded on the carrier, and an adjuvant/antigen co-delivery vaccine formed by the adjuvant and an antigen. The pachyman nanometer adjuvant can promote dendritic cell maturation, enhance lymphocyte function, facilitate drug release, effectively prolong drug effect, prevent immune tolerance, and greatly enhance immune effect and reaction time. The adjuvant/antigen co-delivery vaccine enhances the bioavailability of pachyman and antigen, enables the antigen and the adjuvant to be ingested by the same cell, greatly enhances the targeting property of the vaccine, and can induce not only humoral immunity but also stronger cellular immunity. The invention is used as a novel adjuvant and vaccine, and can be expected to be used for preventing and treating human diseases.